KRAS, an EGFR-induced cell signaling downstream mediator, has been found to be mutated in about 25% of Non-small cell lung cancer (NSCLC) cases, whereas in melanoma, KRAS mutations are rare and found in only 1.7% of the cases [108,109]. Here, EGFR is linked to non-small cell lung carcinoma.